Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Myelodysplastic Syndromes 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Uveal Melanoma 1Recurrence 1Oligodendroglioma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Graft vs Host Disease 1Gliosarcoma 1Glioma 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9Radiosurgery 8atezolizumab 7abemaciclib 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × Vorinostat × Clear all
NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

The Methodist Hospital Research Institute

Phase 1 Active not recruiting
28 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡